What just happened? Sorrento Therapeutics, Inc. (NASDAQ:SRNE) stock value has climbed by nearly 2.84% or (0.11 points) to $3.84 from its previous close of $3.73. Does this growth mean it the best stock to buy right now? The shares seem to have an active trading volume day with a reported 5532563 contracts so far this session. SRNE shares had a relatively better volume day versus average trading capacity of 3.78 million shares, but with a 0.11 billion float and a 19.94% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for SRNE stock indicates that the average analyst price target is $24.5 per share. This means the stock has a potential increase of 538.02% from where the SRNE share price has been trading recently which is between $3.3401 and $4. There are some brokerage firms that offer lower targets than the average, with one of them, even setting their price target at $21. Flipping the other side of the coin, an analyst who is fully bullish set a price target as high as $28.
During the recent trading session for Sorrento Therapeutics, Inc. (NASDAQ:SRNE), the company witnessed their stock rise $0.88 over a week and surge $2.2 from the price 20 days ago. When compared to their established 52-week high of $6.5, the high they recorded in their recent session happens to be lower. Their established 52-week high was attained by the company on 03/22/19. The recent low of $1.39 stood for a -40.99% since 11/10/19, a data which is good for most investors who are looking to take advantage of the stock’s recent rise. A beta of 2.74 is also allocated to the stock. Since the beta is greater than one, it implies that the stock is more volatile than the market, a data that traders are keeping close attention to. At the moment, the median target price for SRNE is set at $24.5, a figure which is above the recent 1-year high the stock witnessed.
Looking at the current readings for Sorrento Therapeutics, Inc., the two-week RSI stands at 83.03. This figure suggests that SRNE stock, for now, is oversold, meaning that the shares are not stable in terms of price movement. The stochastic readings, on the other hand, based on the current SRNE readings is similarly very revealing as it has a stochastic reading of 90.49% at this stage. This figure means that SRNE share price today is being oversold.
Technical chart claims that Sorrento Therapeutics, Inc. (SRNE) would settle between $4.04/share to $4.35/share level. However, if the stock price goes below the $3.38 mark, then the market for Sorrento Therapeutics, Inc. becomes much weaker. If that happens, the stock price might even plunge as low as $3.03 for its downside target. The stock is currently in the green zone of MACD, with the indicator reading 0.77. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.
Analysts at JMP Securities, assumed coverage of SRNE assigning Mkt Outperform rating, according to their opinion released on October 07. B. Riley FBR, Inc., analysts launched coverage of Sorrento Therapeutics, Inc. (NASDAQ:SRNE) stock with a Buy recommendation, according to their flash note issued to investors on June 28. Analysts at H.C. Wainwright are sticking to their Buy stance. However, on January 16, they lifted price target for these shares to $30 from $20.
SRNE equity has an average rating of 1.75, with the figure leaning towards a bullish end. 2 analysts who tracked the company were contacted by Reuters. Amongst them, 0 rated the stock as a hold while the remaining 2 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while no rated it as a sell. 2 analysts rated Sorrento Therapeutics, Inc. (NASDAQ:SRNE) as a buy or a strong buy while not a single analyst advised that investors should desist from purchasing the stock or sell them if they already own the company’s stock.
Sorrento Therapeutics, Inc. (SRNE)’s current-quarter revenues are projected to climb by nearly 6.8% to hit $7.4 million, based on current consensus estimate. The firm’s full-year revenues are expected to expand by over 26.2% from $21.19 million to a noteworthy $26.74 million. At the other end of the current quarter income statement, Sorrento Therapeutics, Inc. is expected to see its adjusted earnings surge by roughly 7.3% to hit $-0.38 per share. For the fiscal year, SRNE’s earnings are projected to climb by roughly -8.3% to hit $-2.08 per share.